• The panel recognized that standard care for hospitalized patients with COVID-19 would include a heparin to prevent venous thromboembolic events (prophylaxis). and therefore did not consider the question of heparin (at any dose) compared to no heparin.
• The recommendation is consistent with the current standard of care for venous thromboembolism prophylaxis in the majority of hospitalized patients.The majority of trials that informed this recommendation evaluated unfractionated or low-molecular-weight heparin. The panel therefore judged that this recommendation applies to both types of heparins.
• The panel judged that this recommendation does not apply to patients with an established indication for therapeutic anticoagulation, for example, confirmed venous thromboembolism Prophylactic dosing of heparins includes dalteparin 400 units daily, enoxaparin 40 mg daily, tinzaparin 4500 units daily, and unfractionated heparin 5000 units twice daily (all subcutaneous), with dose adjustment for elevated body mass index.

Practical info Prophylactic dosing of heparins includes dalteparin 400 units daily, enoxaparin 40 mg daily, tinzaparin 4500 units daily, and unfractionated heparin 5000 units twice daily (all subcutaneous), with dose adjustment for elevated body mass index.